Literature DB >> 28695544

Performance-Based Risk-Sharing Arrangements: An Updated International Review.

Josh J Carlson1, Shuxian Chen2, Louis P Garrison2.   

Abstract

Enthusiasm for performance-based risk-sharing arrangements (PBRSAs) continues but at variable pace across countries. Our objective was to identify and characterize publicly available cases and related trends for these arrangements. We performed a review of PBRSAs from 1993 to 2016 using the University of Washington PBRSA Database. Arrangements were categorized according to a previously published taxonomy. Macro-level trends were identified related to the timing of adoption, countries involved, types of arrangements, and disease areas. Our search yielded 437 arrangements. Among these, 183 (41.9%) were categorized as currently active, while 58.1% have expired. Five main types of arrangements have been identified, namely coverage with evidence development (149 cases, 34.1%), performance-linked reimbursement (104 cases, 23.8%), conditional treatment continuation (78 cases, 17.8%), financial or utilization (71 cases, 16.2%), and hybrid schemes with multiple components (35 cases, 8.0%). The pace of adoption varies across countries but has renewed an upward trend after a lull in 2012/2013. Conditions in the USA may be changing toward a more favorable environment of PBRSAs. Interest in PBRSAs remains high, suggesting they are a viable coverage and reimbursement mechanism for a wide range of medical products.

Mesh:

Year:  2017        PMID: 28695544     DOI: 10.1007/s40273-017-0535-z

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  13 in total

1.  Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.

Authors:  Louis P Garrison; Josh J Carlson; Preeti S Bajaj; Adrian Towse; Peter J Neumann; Sean D Sullivan; Kimberly Westrich; Robert W Dubois
Journal:  Am J Manag Care       Date:  2015-09       Impact factor: 2.229

2.  Risk-sharing agreements for innovative drugs: a new solution to old problems?

Authors:  Gérard de Pouvourville
Journal:  Eur J Health Econ       Date:  2006-09

3.  Medicare's national coverage decisions for technologies, 1999-2007.

Authors:  Peter J Neumann; Maki S Kamae; Jennifer A Palmer
Journal:  Health Aff (Millwood)       Date:  2008 Nov-Dec       Impact factor: 6.301

4.  Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Authors:  Louis P Garrison; Adrian Towse; Andrew Briggs; Gerard de Pouvourville; Jens Grueger; Penny E Mohr; J L Hans Severens; Paolo Siviero; Miguel Sleeper
Journal:  Value Health       Date:  2013-07-19       Impact factor: 5.725

Review 5.  Differential pricing of new pharmaceuticals in lower income European countries.

Authors:  Zoltán Kaló; Lieven Annemans; Louis P Garrison
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2013-12       Impact factor: 2.217

Review 6.  Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

Authors:  Josh J Carlson; Sean D Sullivan; Louis P Garrison; Peter J Neumann; David L Veenstra
Journal:  Health Policy       Date:  2010-03-11       Impact factor: 2.980

7.  When do performance-based risk-sharing arrangements make sense?

Authors:  Michael Drummond
Journal:  Eur J Health Econ       Date:  2015-07

8.  Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?

Authors:  Richard Edlin; Peter Hall; Klemens Wallner; Christopher McCabe
Journal:  Value Health       Date:  2014-04-29       Impact factor: 5.725

9.  The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.

Authors:  Christine Y Lu; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2007-03-01

10.  Health economic value of an innovation: delimiting the scope and framework of future market entry agreements.

Authors:  Robert Launois; Lucia Fiestas Navarrete; Olivier Ethgen; Jean-Gabriel Le Moine; René Gatsinga
Journal:  J Mark Access Health Policy       Date:  2014-06-23
View more
  13 in total

Review 1.  The Australian Managed Entry Scheme: Are We Getting it Right?

Authors:  Haitham W Tuffaha; Paul A Scuffham
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

2.  Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?

Authors:  Fernando Antoñanzas; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

Review 3.  The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

Authors:  Fernando Antonanzas; Carmelo Juárez-Castelló; Reyes Lorente; Roberto Rodríguez-Ibeas
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

Review 4.  Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.

Authors:  Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Value Health       Date:  2020-03-26       Impact factor: 5.725

5.  Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.

Authors:  Amy Gye; Stephen Goodall; Richard De Abreu Lourenco
Journal:  Pharmacoeconomics       Date:  2022-10-21       Impact factor: 4.558

6.  The economics of alternative payment models for pharmaceuticals.

Authors:  Jakub P Hlávka; Jeffrey C Yu; Dana P Goldman; Darius N Lakdawalla
Journal:  Eur J Health Econ       Date:  2021-03-16

7.  The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.

Authors:  Sabine Elisabeth Grimm; Mark Strong; Alan Brennan; Allan J Wailoo
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

8.  The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.

Authors:  Alessandra Ferrario; Diāna Arāja; Tomasz Bochenek; Tarik Čatić; Dávid Dankó; Maria Dimitrova; Jurij Fürst; Ieva Greičiūtė-Kuprijanov; Iris Hoxha; Arianit Jakupi; Erki Laidmäe; Olga Löblová; Ileana Mardare; Vanda Markovic-Pekovic; Dmitry Meshkov; Tanja Novakovic; Guenka Petrova; Maciej Pomorski; Dominik Tomek; Luka Voncina; Alan Haycox; Panos Kanavos; Patricia Vella Bonanno; Brian Godman
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

9.  Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

Authors:  Rick A Vreman; Thomas F Broekhoff; Hubert Gm Leufkens; Aukje K Mantel-Teeuwisse; Wim G Goettsch
Journal:  Int J Environ Res Public Health       Date:  2020-11-10       Impact factor: 3.390

10.  Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.

Authors:  Mohamed Gad; Ahmed Salem; Wija Oortwijn; Ruaraidh Hill; Brian Godman
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.